Last reviewed 2026-06-03 · How we verify

Artromed (AMTOLMETIN GUACIL)

Phase 2 active Small molecule ✓ Verified Jun 2026

Artromed (generic name: AMTOLMETIN GUACIL) is a drug. It is currently in Phase 2 development.

Artromed works by interacting with specific biological pathways to produce its therapeutic effects.

Artromed is a small molecule with the synonyms including Artromed. It is being studied in clinical trials for conditions such as Neurofibromatosis Type 1 and Muscle Weakness, with interventions including whole-body vibration and muscle strengthening exercises.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMTOLMETIN GUACIL
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a orchestra, and each cell plays a specific role. Artromed is like a conductor that helps the cells work together in harmony to produce the right response. By interacting with specific biological pathways, Artromed can help to reduce inflammation and pain, but the exact details of how it does this are still not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Amtolmetin Gaucil in Knee Osteoarthritis

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Artromed CI brief — competitive landscape report
Artromed updates RSS · CI watch RSS

Frequently asked questions about Artromed

What is Artromed?

Artromed (AMTOLMETIN GUACIL) is a Small molecule drug.

How does Artromed work?

Artromed works by interacting with specific biological pathways to produce its therapeutic effects.

What is the generic name of Artromed?

AMTOLMETIN GUACIL is the generic (nonproprietary) name of Artromed.

What development phase is Artromed in?

Artromed is in Phase 2.

Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing